AntiagingAtlanta

Christ ER - J Clin Endocrinol Metab - 01-APR-2004; 89(4): 1801-7
From NIH/NLM MEDLINE
NLM Citation ID:
15070948 (PubMed)
Full Source Title:
Journal of Clinical Endocrinology and Metabolism
Publication Type:
Clinical Trial; Journal Article; Randomized Controlled Trial
Language:
English
Author Affiliation:
Department of Endocrinology and Diabetology, University Hospital of Bern, Bern CH-3100, Switzerland.
Authors:
Christ ER; Cummings MH; Jackson N; Stolinski M; Lumb PJ; Wierzbicki AS; Sönksen PH; Russell-Jones DL; Umpleby AM
Abstract:
GH replacement therapy has been shown to improve the dyslipidemic condition in a substantial proportion of patients with adult HGH deficiency. The mechanisms are not yet fully elucidated. Low-density lipoprotein (LDL) apolipoprotein B100 (apoB) formation and catabolism are important determinants of plasma cholesterol concentrations. This study examined the effect of HGH replacement therapy on LDL apoB metabolism using a stable isotope turnover technique. LDL apoB kinetics was determined in 13 adult patients with HGH deficiency before and after 3 months GH/placebo treatment in a randomized, double-blind, placebo-controlled study. LDL apoB (13)C-leucine enrichment was determined by isotope-ratio mass spectrometry. Plasma volume was assessed by standardized radionuclide dilution technique. GH replacement therapy significantly decreased LDL cholesterol, LDL apoB concentrations, and LDL apoB pool size compared with placebo. Compared with baseline, GH replacement therapy resulted in a significant increase in plasma volume and fractional catabolic rate, whereas LDL formation rate remained unchanged. LDL lipid content did not significantly change after GH and placebo. This study suggests that short-term GH replacement therapy decreases the LDL apoB pool by increasing removal of LDL particles without changing LDL composition or LDL apoB production rate. In addition, it is possible that the beneficial effects of HGH on the cardiovascular system contribute to these findings.
Major Subjects:

• Apolipoproteins B / * blood
• Human Growth Hormone / * therapeutic use
• Hormone Replacement Therapy
• Human Growth Hormone / * blood / * deficiency
• Lipoproteins, LDL / * blood

Additional Subjects:

• Body Composition
• Carbon Isotopes
• Double-Blind Method
• Female
• Hemoglobin A, Glycosylated / metabolism
• Humans
• Insulin / blood
• Insulin-Like Growth Factor I / metabolism
• Kinetics
• Lipids / blood
• Male
• Metabolism, Inborn Errors / blood / drug therapy
• Research Support, Non-U.S. Gov't

Chemical Compound Name:
(Apolipoproteins B); (Carbon Isotopes); (Hemoglobin A, Glycosylated); (Lipids); (Lipoproteins, LDL); (apolipoprotein B-100); 11061-68-0(Insulin); 12629-01-5(Human Growth Hormone); 67763-96-6(Insulin-Like Growth Factor I); 9002-72-6(Human Growth Hormone)